Protalix (PLX) Director Ben Zvi Shmuel Receives 25,500-Share Award

What Happened

• Ben Zvi Shmuel, a director of Protalix BioTherapeutics (PLX), received two derivative awards on 2026-09-03 totaling 25,500 units: 17,000 and 8,500. The reported price is $0.00 (i.e., these are grants/awards, not open-market purchases or sales). The Form 4 does not list a cash value for the awards.

Key Details

• Transaction date: 2026-09-03; Form 4 filed 2026-09-04 (timely).
• Reported amounts: 17,000 and 8,500 derivative shares (25,500 total); reported price per unit $0.00.
• Shares owned after transaction: not specified in the filing.
• Notable footnotes:
  • F3/F4: Each restricted stock unit (RSU) equals the right to receive one share upon vesting; RSUs vest in 12 equal quarterly installments commencing on the grant date.
  • F1: The shares underlying stock options (if any portion of the grant are options) also vest in 12 equal quarterly installments.
  • F2: The filing separately notes other outstanding options not part of this grant: 40,000 @ $1.09 (exp. 6/30/2032); 10,000 @ $1.03 (exp. 9/7/2032); 61,676 @ $1.66 (exp. 9/29/2033); 15,000 @ $1.64 (exp. 9/3/2035).
• Filing timeliness: Filed one day after the transaction date—no late filing flag.

Context

• These were compensation awards (derivative grants such as RSUs and/or option grants) that vest over 12 quarterly installments (about three years). RSUs convert to shares only after vesting; option grants (if applicable here) would require exercise at a stated strike price to acquire shares. These awards are routine compensation/retention instruments and are not the same as an open-market purchase or sale.